# First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report

## TL;DR

A patient with ALK-rearranged lung cancer that transformed into small cell lung cancer responded well to tarlatamab treatment.

## Contribution

First reported case of successful tarlatamab treatment in histologically transformed SCLC from ALK-rearranged NSCLC.

## Key findings

- The patient showed clinical benefit from tarlatamab after progressing on multiple therapies.
- Intracranial response was observed, indicating effective treatment of brain metastases.

## Abstract

Small cell transformation has been described as a resistance mechanism to targeted therapy treated in patients with EGFR-mutated NSCLC and less often reported with those with other actionable oncogenic alterations, including ALK-rearranged NSCLC. Given lack of standard-of-care treatments for patients with actionable oncogenic alteration NSCLC transformed to SCLC, this remains a challenge and unmet need for treating these patients.

Here, we present a case of a patient with ALK-rearranged NSCLC with transformation to SCLC, who has progressed on several lines of therapies and successfully treated with tarlatamab to elicit and maintain clinical benefit, including intracranial response.